- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01594346
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome
May 8, 2012 updated by: Arthur Dalton, New York State Institute for Basic Research
The purpose of this study is to determine the safety and effectiveness of 2,000 international units of Vitamin E (alpha tocopherol)on cognitive function of aging persons with Down syndrome.
It is a randomized, double-blind, placebo-controlled trial lasting 36 months.
It is expected that Vitamin E will slow the deterioration in cognitive functions associated with Alzheimer disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Alzheimer disease (AD) continues to be the most serious health problem faced by aging persons with Down syndrome.
AD is also a major public health concern in the aging general population.
With increasing life expectancy there will be a dramatic increase in the prevalence of AD cases, which will pose a significant increased burden on the health care system and individual providers of care.
Persons with Down syndrome are uniquely vulnerable to a form of Alzheimer disease indistinguishable from the sporadic variety that affects aging individuals from the general population.
Oxidative damage is a highly plausible mechanism in the pathogenesis of this disease due to the overexpression of superoxide dismutase, associated with a gene located on chromosome 21, which is present in triplicate in the Down syndrome genotype.
For the last six years, we have been conducting a clinical trial to determine the safety and efficacy of the anti-oxidant Vitamin E in slowing the cognitive and functional decline associated with the dementia of AD among individuals with DS.
The study is a randomized, double-blind trial, stratified in a two-arm parallel design.
The subjects are medically stable individuals who are 50 years of age or older at the time of screening.
Among those randomized to the treatment arm, vitamin E is taken in the form of 1000 IU capsules for 36 months.
Each subject is evaluated every 6 months for 3 years.
The primary outcome is is the Brief Praxis Test (BPT), which is well-suited to quantifying cognitive decline in this population.
The target enrollment of 350 persons is estimated to be sufficient to provide adequate statistical power to detect a slowing by one-third in the rate of cognitive decline with vitamin E treatment.
The Data and Safety Monitoring Board (DSMB) for this trial includes 4 physicians, and a statistician with expertise in clinical trials.
Each DSMB member receives a report on each serious adverse event (SAE) on a flow basis, and statistically summaries of unblinded safety data--including deaths, adverse events and vital signs--prior to each meeting of the DSMB.
The most recent DSMB meeting took place on February 23,2010.
The timeline for study completion is: recruitment of the study sample (N=350) was completed on 12/31/2008; the final 36-month evaluation will take place in 04/2010; statistical analysis and final report of results is expected to be completed by 12/31/2010.
Study Type
Interventional
Enrollment (Actual)
349
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- presence of clinically determined Down syndrome (karyotypes optional)
- appropriately signed and witnessed consent form
- age of 50 years or older at the start of the protocol
- medically stable
- medications stable more than 1 month
- involvement/cooperation of informant/caregiver
Exclusion Criteria:
- medical/neurological condition (other than Alzheimer disease) associated with dementia
- inability to adequately perform the Brief Praxis Test, as demonstrated by a score <20
- in the presence of dementia, modified Hachinski score > 4 at Screening Visit
- major depression within 3 months
- history of coagulopathy (inherited or acquired)
- current use of anticoagulants
- use of experimental medications within 2 months
- regular use of vitamin E greater than 50 units per day during the previous 6 months
- allergy to vitamin E
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar Pill
|
|
Active Comparator: Alpha-Tocopherol
|
1,000 International Units, two times a day for 36 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Brief Praxis Test
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Fuld Object Memory Test
Time Frame: 36 Months
|
36 Months
|
New Dot Test
Time Frame: 36 Months
|
36 Months
|
Orientation Test
Time Frame: 36 Months
|
36 Months
|
Vocabulary Test
Time Frame: 36 Months
|
36 Months
|
Behavior and Function
Time Frame: 36 Months
|
36 Months
|
Clinical Global Impression
Time Frame: 36 Months
|
36 Months
|
Incident Dementia
Time Frame: 36 Months
|
36 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Paul S. Aisen, M.D., University of California, San Diego
- Study Director: Mary C. Sano, Ph.D., Bronx Veterans Medical Research Foundation
- Study Director: Howard F. Andrews, Ph.D., New York Psychiatric Institute
- Study Director: Wei-Yann Tsai, Ph.D., Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2000
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
May 2, 2012
First Submitted That Met QC Criteria
May 8, 2012
First Posted (Estimate)
May 9, 2012
Study Record Updates
Last Update Posted (Estimate)
May 9, 2012
Last Update Submitted That Met QC Criteria
May 8, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Intellectual Disability
- Dementia
- Tauopathies
- Abnormalities, Multiple
- Chromosome Disorders
- Syndrome
- Alzheimer Disease
- Down Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Vitamin E
- Tocopherols
- alpha-Tocopherol
- Tocotrienols
Other Study ID Numbers
- NCT00056329
- R01AG016381 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Down Syndrome
-
Rachel G. Greenberg, MD, MB, MHSEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsNot yet recruitingHyperactivity in Children With Down Syndrome | Impulsivity in Children With Down Syndrome
-
Riphah International UniversityCompletedDown S SyndromePakistan
-
Hoffmann-La RocheCompletedHealthy Volunteer, Down SyndromeUnited Kingdom
-
Cairo UniversityCompleted
-
Institute of Child HealthCompleted
-
Vanderbilt University Medical CenterNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingSpeech Intelligibility Intervention in Down SyndromeUnited States
-
Marmara UniversityCompletedStair up and Down, Amputation | Amputation,Stair up and DownTurkey
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico
-
Eastern Mediterranean UniversityCompletedDown Syndrome, Trisomy 21Cyprus
-
Institut Jerome LejeuneFondation Jérôme LejeuneCompletedDown Syndrome With and Without Auto Immune AbnormalitiesFrance
Clinical Trials on Sugar Pill
-
Massachusetts General HospitalGaneden Biotech, Inc.TerminatedIrritable Bowel Syndrome | Major Depressive DisorderUnited States
-
Harvard University Faculty of MedicineBeth Israel Deaconess Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Hospital de Clinicas de Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompletedPeriampullary Carcinoma NosBrazil
-
GlaxoSmithKlineCompletedHealthy Subjects | Infections, BacterialAustralia
-
USDA Grand Forks Human Nutrition Research CenterCompletedInsomnia | Nutritional DeficiencyUnited States
-
Neurotune AGCross Research S.A.; Triclinium clinical trial project managment LTDCompletedNeuropathy | AIDSSouth Africa
-
Vantia LtdVeeda Clinical ResearchCompleted
-
University of California, Los AngelesCompletedAutism Spectrum DisorderUnited States
-
University of California, Los AngelesCompleted
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed